Portland, OR, September 26, 2011 --(PR.com
)-- HealthSaaS, Inc. has announced an expansion of their strategic alliance with BioSign Technologies Inc. (TSXV: BIO). Today’s announcement adds the Cloud Dx solution and non-invasive blood glucose measurements to the HealthSaaS Connected Outcomes Framework®.
Frank Ille, CEO, HealthSaaS states, “Our partnership will allow our Connected Outcomes Framework to deliver a broad range of data and analytics that will measurably improve the quality of life for patients and lower costs to providers and payers.”
The CloudDxTM solution and UFIT® device integrated with HealthSaaS Connected Outcomes Framework deliver sophisticated, reliable personal health monitoring that augments patient and disease management. The alliance provides accurate, secure vitals monitoring, including blood pressure and glucose analysis with integrated real-time reporting to the complete circle of care (patient, family, nurses, physicians, healthcare provider, and payer).
Scott Jenkins, CEO, BioSign states “Our New Cloud Dx solution and non-invasive blood glucose data integrated with HealthSaaS Connected Outcomes Framework is a significant step forward to facilitating seamless collaboration and providing quality metrics for the healthcare ecosystem. By working together, we will lower costs for payers and improve the quality of life for patients with diabetes, hypertension, and cardio-vascular diseases.”
About HealthSaaS, Inc.
HealthSaaS (HSI) is leading the Health 2.0 movement by creating cloud based health information technology solutions. Our patent pending Connected Outcomes Framework can aggregate disparate data from many sources including mHealth applications, cloud based services, Telehealth solutions and connected medical devices. The framework removes silo barriers and makes data available to clinician practices, provider networks, payors, self funded employers and EHRs.www.healthsaas.net
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Cloud Dx applications include intelligent systems for non-invasive monitoring of common health risks associated with blood pressure, glucose, and medication. Biosign technology combines measurement, analysis, and tools for disease and patient management to support global vital health monitoring. The UFIT® medical device delivers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation and management, and remote patient monitoring. For more information visit: www.biosign.com
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.